Staley Capital Advisers Inc. Makes New $581,000 Investment in Standard BioTools Inc. $LAB

Staley Capital Advisers Inc. bought a new stake in Standard BioTools Inc. (NASDAQ:LAB) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 632,392 shares of the company’s stock, valued at approximately $581,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Casdin Capital LLC increased its stake in shares of Standard BioTools by 14.5% in the fourth quarter. Casdin Capital LLC now owns 88,783,856 shares of the company’s stock worth $113,643,000 after buying an additional 11,225,000 shares during the last quarter. Mak Capital One LLC boosted its stake in Standard BioTools by 21.1% during the 4th quarter. Mak Capital One LLC now owns 19,288,158 shares of the company’s stock valued at $24,689,000 after acquiring an additional 3,356,352 shares during the last quarter. Vanguard Group Inc. boosted its stake in Standard BioTools by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 17,245,583 shares of the company’s stock valued at $22,419,000 after acquiring an additional 263,845 shares during the last quarter. Long Focus Capital Management LLC grew its holdings in Standard BioTools by 12.8% during the 3rd quarter. Long Focus Capital Management LLC now owns 11,362,804 shares of the company’s stock worth $14,772,000 after acquiring an additional 1,292,804 shares in the last quarter. Finally, State Street Corp grew its holdings in Standard BioTools by 1.3% during the 4th quarter. State Street Corp now owns 6,482,766 shares of the company’s stock worth $8,298,000 after acquiring an additional 80,117 shares in the last quarter. 53.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Standard BioTools from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Weiss Ratings downgraded Standard BioTools from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 27th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Standard BioTools has an average rating of “Reduce” and an average price target of $1.35.

Standard BioTools Trading Down 1.9%

LAB stock opened at $0.88 on Thursday. The firm has a market cap of $344.11 million, a P/E ratio of 4.41 and a beta of 1.42. Standard BioTools Inc. has a 12-month low of $0.70 and a 12-month high of $1.72. The stock’s 50 day simple moving average is $0.95 and its 200 day simple moving average is $1.10.

Standard BioTools Company Profile

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.